NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

Slave1 -

“We have always been quite interested in regional partnering or licensing… Asia, Latin America, the Gulf… and we’ve worked hard and spent a lot of money to file our patents in all these various countries so that we would have the ability to do these kind of deals.” - Linda Powers 12/29/25


After DCVax gets its first approval, Saudi is easy because SFDA already has fast follow pathways for reference approved medicines, CAR T has already been deployed at scale with local manufacturing in Saudi centers, and SFDA rules explicitly support under license structures that anchor manufacturing locally, which is exactly what an autologous platform needs to scale.

Andrew’s post highlights a massive structural pivot that many retail investors are missing: DCVax is moving from a "drug" to a "Sovereign Asset."
When you combine Linda Powers' licensing strategy with Cofer Black's operational background, you see a masterclass in Geopolitical Tradecraft. They aren't just looking for "partners"; they are anchoring DCVax into the national security and healthcare infrastructure of the world’s wealthiest sovereign nations.

The UK’s Sovereign Security Asset Protection architecture (launched in early 2026) is the key. It isn't just about cybersecurity; it's about Data and Biological Sovereignty.
Cofer Black’s Fingerprints: As a former Director of the CIA’s Counterterrorist Center, Black understands that a personalized medicine platform like DCVax—which requires the handling of sensitive patient genetic and biological data—must be protected from foreign interference.
The UK Anchor: By aligning with the UK’s new sovereign platforms, NWBO ensures that DCVax-L is treated as a Critical National Asset. This makes it nearly impossible for predatory shorts or hostile foreign entities to disrupt the manufacturing and data pipelines at Sawston.
Andrew is spot on regarding the SFDA (Saudi Food and Drug Authority). Saudi Arabia is currently the most aggressive "fast-mover" in the Gulf, and their regulations are tailor-made for an autologous (patient-specific) platform like DCVax.

The Long Game-
This isn't "hopium"; it's a Regulatory Extraction.
The Saudi Example: By manufacturing locally, Saudi Arabia reduces the cost of personalized therapies from millions of SAR to roughly 250,000 SAR per patient. This makes DCVax-L a sustainable, high-margin, national-level treatment.
The "consortium": Cofer Black is the only board member with the pedigree to talk "Sovereign to Sovereign." If he is bringing a consortium of wealth funds together under the UK’s protective umbrella, he is effectively creating a Financial Firewall that the 7 Market Makers cannot pierce.